Shots:

• Endo to acquire all the outstanding shares of BioSpecifics for $88.50/ share in cash- making a total deal value of $540M. The transaction is expected to close in late 2020 while Endo expects to fund the transaction with cash on hand
• BioSpecifics receives a royalty stream related to Endo's collagenase-based therapies- which include Xiaflex for Dupuytren's contracture and Peyronie's disease- and Qwo for cellulite- which is expected to be launched by Endo in spring 2021
• Endo's acquisition subsidiary will be merged into BioSpecifics- and the remaining shares of BioSpecifics will be canceled and converted into the right to receive the same consideration payable pursuant to the tender offer

­ Ref: PRNewswire | Image: Seeking Alpha